University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

CYP2D6 genotype predicts tamoxifen discontinuation and drug response : a secondary analysis of the KARISMA trial

Simple item page
dc.contributor.authorHe, W.
dc.contributor.authorEriksson, M.
dc.contributor.authorEliasson, E.
dc.contributor.authorGrassmann, F.
dc.contributor.authorBäcklund, M.
dc.contributor.authorGabrielson, M.
dc.contributor.authorHammarström, M.
dc.contributor.authorMargolin, S.
dc.contributor.authorThorén, L.
dc.contributor.authorWengström, Y.
dc.contributor.authorBorgquist, S.
dc.contributor.authorHall, P.
dc.contributor.authorCzene, K.
dc.contributor.institutionUniversity of Aberdeen.Medical Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Institute of Medical Sciencesen
dc.date.accessioned2022-11-30T16:52:00Z
dc.date.available2022-11-30T16:52:00Z
dc.date.issued2021-10-01
dc.descriptionFunding Information: This work was supported by Märit and Hans Rausing's Initiative Against Breast Cancer (no grant number); the Kamprad Foundation [grant number: 20150052 ]; and Stockholm County Council [grant number: 4-2645/2015 ]; the Swedish Research Council [grant number 2018-02547 ]; the Swedish Cancer Society [grant number 19 0266 ]; and Swedish Research Council for Health, Working Life and Welfare (FORTE) [grant number 2016-00081 , 2018-00877 ]. WH is supported by Zhejiang University through ‘Hundred Talents Program’ (no grant number). The funding source had no role in study design, collection, analysis, or interpretation of the data, the writing of the manuscript, or the decision to approve publication of the finished manuscript.en
dc.description.statusPeer revieweden
dc.format.extent8
dc.format.extent133817
dc.identifier198923882
dc.identifier2ae584fc-31c9-4bb6-a911-b4275de9ef17
dc.identifier85112111245
dc.identifier34284099
dc.identifier.citationHe, W, Eriksson, M, Eliasson, E, Grassmann, F, Bäcklund, M, Gabrielson, M, Hammarström, M, Margolin, S, Thorén, L, Wengström, Y, Borgquist, S, Hall, P & Czene, K 2021, 'CYP2D6 genotype predicts tamoxifen discontinuation and drug response : a secondary analysis of the KARISMA trial', Annals of Oncology, vol. 32, no. 10, pp. 1286-1293. https://doi.org/10.1016/j.annonc.2021.07.005en
dc.identifier.doi10.1016/j.annonc.2021.07.005
dc.identifier.iss10en
dc.identifier.issn0923-7534
dc.identifier.otherORCID: /0000-0003-1390-7528/work/99292874
dc.identifier.urihttps://hdl.handle.net/2164/19658
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85112111245&partnerID=8YFLogxKen
dc.identifier.vol32en
dc.language.isoeng
dc.relation.ispartofAnnals of Oncologyen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectbreast canceren
dc.subjectCYP2D6 genotypeen
dc.subjectmammographic densityen
dc.subjecttamoxifenen
dc.subjecttreatment discontinuationen
dc.subjectR Medicineen
dc.subjectHematologyen
dc.subjectOncologyen
dc.subjectOtheren
dc.subjectSupplementary Dataen
dc.subject.lccRen
dc.titleCYP2D6 genotype predicts tamoxifen discontinuation and drug response : a secondary analysis of the KARISMA trialen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
He_etal_AO_CYP2D6_Genotype_Predicts_VoR.pdf
Size:
130.68 KB
Format:
Adobe Portable Document Format
Download

Collections

All research